Navigation Links
Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
Date:11/1/2007

ALLEGAN, Mich., Nov. 1 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has settled its patent litigation with AstraZeneca (the manufacturer of Prilosec OTC(R)) involving three Orange Book patents ('380, '230 and '505) relating to the product. While terms and conditions of the agreement have not been disclosed, the amicable settlement and dismissal with prejudice of the litigation will allow for commercialization of the product once Dexcel receives final regulatory approval from the U.S. Food & Drug Administration. Based upon Dexcel's estimated FDA approval date, Perrigo should be in a position to launch the product by the end of first quarter calendar year 2008.

Dexcel had filed its New Drug Application (NDA) with a Paragraph IV Certification stating that AstraZeneca's patents are invalid, unenforceable, or will not be infringed under the NDA. In May 2006, AstraZeneca filed a patent infringement suit to prevent Dexcel from commercialization of its product. The settlement between Dexcel and AstraZeneca resolves this litigation with AstraZeneca waiving forever its claims regarding the three Orange Book patents relating to Dexcel's product.

Under terms of an agreement between Dexcel and Perrigo, Perrigo will be the exclusive marketer and distributor for the store brand over-the-counter market in the United States of the Dexcel-developed and manufactured product. Perrigo expects full year annual sales for the product to be in the range of $150 - $200 million. Perrigo will provide more detailed information on the financial impact to fiscal year 2008 follo
'/>"/>

SOURCE Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23 (HealthDay News) -- A shortage of a critical ... across the United States to contain the spread of ... The drug, isoniazid (INH), was first used in 1951 ... the core of any first-line treatment for tuberculosis (TB). ... months, according to the U.S. Centers for Disease Control ...
(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...
(Date:5/23/2013)... 2013 Netsmart today announced it ... of healthcare information technology (HIT) providers for 2013. , The ... of Healthcare Informatics magazine. Netsmart’s ranking of #49 ... strong continued growth is largely due to our commitment to ... of healthcare where resources are scarce, the demand for care ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
Breaking Medicine News(10 mins):Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2
... James S. Forrester, M.D., former chief of the ... the 2009 Lifetime Achievement Award from the American College ... March 29. , Currently the George Burns ... Forrester came to the medical center in 1969 as ...
... These new insights represent an important contribution to future ... prestigious science journal Nature and will be ... molecular mechanisms of hematopoiesis, which will take place in ... findings on the molecular mechanisms of blood formation (hematopoiesis) ...
... Overestimate Amount of Time it Takes to Form a New ... to Achieving Healthier HabitsGREENWICH, Conn., April 1 ... Nestle(R) Pure Life (R) brand bottled water, the number one ... think it takes six months or longer to form a ...
... PALM BEACH GARDENS, Fla., April 1 As ... http://www.silvercensus.com ), a national web ... announced today that it is urging American Veterans ... entitlement from the Veterans Administration called "Aid and ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... April 1 Immunotech Laboratories, Inc. Immunotech Laboratories ... in Puerto Rico with its abstract " Irreversible ... specific novel cytokine stimulation in vitro investigation of ... at the 5th European Conference on Clinical and ...
Cached Medicine News:Health News:ACC presents lifetime achievement award to Cedars-Sinai Heart Institute's James Forrester, M.D. 2Health News:Last step leading to blood cell formation elucidated 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4
(Date:5/23/2013)... -- CAS Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), ... announced that Thomas M. Patton , President ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, ... City . The presentation is scheduled to ... and will be available via a live webcast at ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: